Today

Agents

Chat

Arena

Discover

More

App

Pasithea Therapeutics warrants set to be delisted from Nasdaq upon expiration - KTTA News | Rallies

Pasithea Therapeutics warrants set to be delisted from Nasdaq upon expiration

KTTA•2026-09-16

Warrants set to expire and be delisted

Pasithea Therapeutics’ Nasdaq-listed warrants (KTTAW) will expire on Sept. 17, 2026.
Unexercised warrants will become void at expiration.
Trading in KTTAW will end on Nasdaq, followed by a Form 25 filing to delist the warrants.
Common stock will continue trading on Nasdaq under the symbol KTTA.

Related News

Health Catalyst CEO, director Kohl Simeon files initial beneficial ownership statement

HCAT•2026-09-16

Oil slips as Saudi Arabia offers more crude via Oman

XLE•2026-09-16

Airbnb Chief Strategy Officer Nathan Blecharczyk disposes of 17,692 common shares worth $3.03 million

Sources

S

Pasithea Therapeutics warrants set to be delisted from Nasdaq upon expiration

Sec

ABNB

•

2026-09-16

Toll Brothers declares quarterly dividend of $0.26 per share

TOL•2026-09-16

ProFrac amends Alpine term loan, extends maturity to Feb. 2030

ACDC•2026-09-16